GPR12 (G Protein-Coupled Receptor 12) is an orphan receptor belonging to the rhodopsin-like GPCR family, initially identified through genomic studies. Though its endogenous ligands remain unclear, GPR12 is implicated in regulating neural development, synaptic plasticity, and metabolic processes. It shows high expression in the brain, particularly in regions like the hippocampus and cortex, as well as in adipose tissue and the cardiovascular system. Research suggests its involvement in neurite outgrowth, oligodendrocyte differentiation, and lipid metabolism regulation. GPR12 antibodies are essential tools for studying its localization, expression patterns, and functional roles. These antibodies, often developed in rabbits or mice, target specific epitopes (e.g., extracellular loops or C-terminal domains) and are validated via techniques like Western blotting, immunohistochemistry, or flow cytometry. Their applications span neuroscience (e.g., neurodevelopmental disorders), metabolic disease research (e.g., obesity, diabetes), and cancer studies, where aberrant GPR12 signaling may influence tumor progression. Challenges include verifying specificity due to GPCR structural homology and the receptor’s constitutive activity. Recent interest in GPR12 as a therapeutic target for neurological or metabolic disorders has driven demand for high-affinity antibodies to elucidate its signaling mechanisms and assess drug candidate interactions.